A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations

NCT03634059 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Apatinib

Sponsor

Hebei Medical University Fourth Hospital